Quick Answer
Esperion Therapeutics, Inc. reported Operating Income Loss of $60.27 million for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +10.8% in Operating Income Loss from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$7.89 million | Q2 2014: -$9.25 million | Q3 2014: -$9.70 million | Q4 2014: -$9.38 million | Q1 2015: -$11.43 million | Q2 2015: -$12.46 million | Q3 2015: -$12.92 million | Q4 2015: -$13.23 million | Q1 2016: -$14.82 million | Q2 2016: -$14.33 million | Q3 2016: -$17.71 million | Q4 2016: -$29.29 million | Q1 2017: -$40.89 million | Q2 2017: -$43.66 million | Q3 2017: -$45.74 million | Q4 2017: -$38.70 million | Q1 2018: -$46.89 million | Q2 2018: -$46.48 million | Q3 2018: -$50.56 million | Q4 2018: -$60.65 million | Q1 2019: $86.93 million | Q2 2019: -$55.30 million | Q3 2019: -$65.77 million | Q4 2019: -$58.96 million | Q1 2020: -$74.45 million | Q2 2020: $129.17 million | Q3 2020: -$80.55 million | Q4 2020: -$95.57 million | Q1 2021: -$82.82 million | Q2 2021: -$32.53 million | Q3 2021: -$55.75 million | Q1 2022: -$42.99 million | Q2 2022: -$52.38 million | Q3 2022: -$41.62 million | Q1 2023: -$48.61 million | Q2 2023: -$37.06 million | Q3 2023: -$27.53 million | Q1 2024: $72.27 million | Q2 2024: $2.58 million | Q3 2024: -$16.03 million | Q1 2025: -$22.10 million | Q2 2025: $7.10 million | Q3 2025: -$9.96 million.
- Over the full 15 years of available data (2011 to 2025), Esperion Therapeutics, Inc.'s Operating Income Loss has grown by 693.0%.
- Historical annual values: Fiscal year 2025: $60.27 million | Fiscal year 2024: $54.40 million | Fiscal year 2023: -$155.56 million | Fiscal year 2022: -$179.50 million | Fiscal year 2021: -$226.73 million | Fiscal year 2020: -$121.40 million | Fiscal year 2019: -$93.10 million | Fiscal year 2018: -$204.59 million | Fiscal year 2017: -$168.98 million | Fiscal year 2016: -$76.15 million | Fiscal year 2015: -$50.04 million | Fiscal year 2014: -$36.22 million | Fiscal year 2013: -$22.76 million | Fiscal year 2012: -$10.20 million | Fiscal year 2011: -$10.16 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: